We monitored the responses of solid organ transplant recipients (SOTs) to influenza vaccine during consecutive influenza seasons. Standard 1993-1994 trivalent influenza vaccine was given to 68 SOTs and 29 healthy young adults) and hemagglutination-inhibition (HI) antibody titers were determined pre-and post-immunization. Significant rises in geometric mean antibody titers occurred post-immunization for all three antigens in both groups. However) the magnitude of the rise was lower in SOTs (1.5 -2.3-fold vs. 8.7-lOA-fold, depending on the antigen) (P < .05)) and significantly fewer SOTs had protective HI titers (~1:40) for B/Panama/45 190 antigens (50% of SOTs vs. 76% of healthy subjects) and for A/Texas/36/91 (H1Nl) antigens (60% vs. 90%). After exclusion of persons with high preimmunization titers, SOTs had significantly reduced frequencies of~4·fold
Patients receiving chronic immunosuppressive drug therapies) including those who have undergone solid organ transplantation, are at increased risk for excessive morbidity and death due to influenza virus infections [1] . Transplant recipients appear to be more susceptible to infection and are more likely to experience influenza-related complications, including viral pneumonia, bacterial superinfection) and neurologic complications [2] [3] [4] . Influenza virus infection may also activate the immune system and, in renal transplant recipients, possibly cause graft damage, rejection, and eventual graft loss [5, 6] .
Immunization before each annual influenza season is currently the most effective measure for reducing the impact of influenza [7] . Influenza vaccine administration appears to be safe for transplantation patients; several studies have failed to demonstrate a link between rejection and immunization [8] [9] [10] . However, the immunogenicity and associated protective efficacy of the conventional influenza vaccine appear to be diminished in renal transplant recipients receiving long-term immunosuppressive therapy as compared with those ofthe vaccine in healthy subjects [11] [12] [13] [14] [15] [16] . In some studies of renal transplantation patients, factors that have been associated with poor antibody responses to influenza vaccination have included poor allograft function and treatment with cyclosporine [11, 12, 14] . In contrast, two small studies involving renal transplant recipients have found no association between poor antibody responses to immunization and the dose or duration of immunosuppressive treatment, age of the vaccinee, or allograft function [5, 10] .
Besides the inconsistent data concerning renal transplant recipients, there is limited information regarding other solid organ transplant recipients and their response to influenza immunization. The population of solid organ transplant recipients is a heterogeneous group, and it is not known whether the findings with regard to renal transplant recipients can be generalized to all solid organ transplant patients. The purpose of our study was to assess the immunogenicity of influenza vaccines in representative types of solid organ transplant recipients and to compare their antibody responses to those observed in healthy persons receiving comparable immunization. We also evaluated the impact of other host factors on vaccine response. In addition, we believe our study is the first to evaluate whether the response to immunization in the solid organ transplant recipient can be enhanced by administration of an additional (booster) dose of vaccine.
Methods

Subjects
We performed two separate studies during sequential influenza immunization seasons. The first was a prospective cohort study of conventional influenza immunization, which involved em 1996; 22 (February) a group of solid organ transplant recipients selected from the transplant clinics at the University of Virginia ( Charlottesville, VA) and Hahnemann University Hospital (Philadelphia) and a separate comparison group ofhealthy adult volunteers studied at the University of Virginia. During the second year, an open trial of booster immunization of heart transplant recipients was performed. The studies were approved by the human investigation committees of the respective institutions, and written informed consent was obtained from each subject enrolled in the study. The healthy young adults were compensated for participation.
Cohort Study, [1993] [1994] In the first study, the solid organ transplant recipients and healthy volunteers were studied in parallel during the 1993 fall immunization period. Inclusion criteria for the transplantation patients were the administration of long-term immunosuppressive drug therapy, an interval of at least 2 months since transplant surgery, and age of~6 months. Members of the comparison group were included if they did not have a history of smoking or alcohol abuse, impairment of immunologic function, or major organ diseases and if they were not taking any immunosuppressive medications. To determine the maximal responsiveness to the vaccine, an effort was made to choose subjects for the comparison group who were young and in good health. However, this group was not matched with regard to age or gender. None of the study participants had had an acute febrile illness within 1 week before the vaccination.
The transplantation patients were given immunizations during their routine visits to the clinics between the end of September 1993 and middle of December 1993. The subjects in the comparison group were given the vaccines as they were enrolled in the study during the same time period. Each participant was given one 0.5-mL dose intramuscularly of the standard trivalent vaccine made for the 1993 -1994 season by Connaught Laboratories (Swiftwater, PA). Each dose of vaccine contained 15 J.tg of each hemagglutinin of A/Beijing/32/92 (H3N2), A/Texas/36/91 (H1N1), and B/Panama/45/90-like strains. The site of administration for all subjects was in the deltoid muscle.
Medical history data-which included age, gender, race, prior influenza vaccination history (for 1991 and 1992), and history of smoking, diabetes, and recent illness-were collected for each subject by the study staff. Data regarding vaccination history were unavailable for the comparison group. Additional information obtained with regard to the transplant recipients included height; weight; presence or absence of obesity; type and date of transplantation; type, dosage (mg/ d), and duration (months) of each immunosuppressive drug regimen; and history of organ rejection problems before the current influenza vaccination. Subjects were considered to be obese if their body weight was 20%-30% above the midpoint height/ weight scales on the 1983 tables of the Metropolitan Life Insurance Company (New York).
Samples of whole venous blood (3 -5 mL) were collected from each subject immediately before the vaccine was given, and convalescent serum samples were collected 4-12 weeks later. All serum samples were stored at -20°C until tested.
Booster Immunization Study, [1994] [1995] On the basis of transplant recipient responses to the 1993-1994 influenza vaccine, a second prospective study was designed to determine whether vaccine response could be enhanced by administration of a booster dose of vaccine. After they gave written informed consent, stable heart transplant recipients for whom there were no contraindications for influenza vaccination and who were at least 1 year status post transplantation were given a 0. All ofthe blood samples for a given year were tested simultaneously under blinded conditions by a single technologist. A standard microtiter hemagglutination-inhibition (HI) test using all of the three vaccine antigens was performed [17] .
Results were considered negative if the HI antibody titer was < 1: 10. Ifthe convalescent titer was~1:40, then the patient was considered to be protected against illness by that strain of influenza virus [18, 19] . A patient was considered to have had an antibody response or seroconversion when there was at least a fourfold rise in titer between the acute and convalescent phases or if the acute titer was < 1:10 and the convalescent titer was 1:20.
Data Analysis
The comparison between transplant recipients and healthy subjects was performed with SAS-PC (SAS Institute, Cary, NC). Differences in proportions within each group and between each group were analyzed by means of X2 analysis with 1 degree of freedom or-when the expected cell frequency for any of the cells was < 5-Fisher's exact test (two-tailed).
Continuous variables were compared with the two-sample ttest (for comparisons between groups) and the paired t-test (for comparisons within groups). The average group values of the HI antibody titers are expressed as the geometric means :t SDs. Statistical analyses were calculated for each of the three strains of antigen separately.
Multiple linear regression was perfonned separately for each antigen strain to account for variability in the postimmunization titers attributable to each of the independent variables, after the remaining independent variables were controlled for. Logistic regression, which is used for binary outcome variables, was perfonned separately for each strain in order to detennine the relationship between each of the independent variables and the binary outcome variable (a ;;:::4-fold antibody response vs. a < 4-fold antibody response), after the remaining independent variables were controlled for.
Statistical analysis for the 2-dose vaccine regimen was perfonned with use of Instat (GraphPad Software, San Diego). Repeated-measures analysis ofvariance was perfonned to compare the three time points for each vaccine antigen, and the Tukey-Kramer multiple comparisons test was used to test the effectiveness of the matching. Fisher's exact test was used to evaluate the impact of clinical variables on vaccine response.
Results Prospective Cohort Study
Populations. The primary study population for the 1993-1994 season consisted of 68 transplant recipients (49 males and 19 females); the mean (±SD) age was 52 ± 11 years (range, 24-72 years). There were 34 heart, 8 lung, 13 kidney, and 13 liver transplant recipients. The comparison group consisted of 29 healthy volunteers (13 males and 16 females), aged 23 ± 7 years (mean ± SD; range, 18-47 years). As expected, there was a significant difference in the mean ages of the two groups (P < .001). In addition, the proportion of males was higher in the transplantation group than in the comparison group (P < .05).
Higher baseline HI antibody titers were noted in the transplantation group for all three antigens (table 1) . Similarly, higher proportions of transplantation patients than of healthy volunteers had preimmunization HI antibody titers at a protective level (~1 :40) for two of the three antigens (A/Beijing/ 32/92 and B/Panama/45/90) (table 2) .
Response to irif/uenza immunization. For both the transplantation and comparison groups, significant increases in postimmunization geometric mean HI antibody titers occurred for each of the three antigens (table 1) . However, the magnitudes of the rises in antibody titer were significantly lower for the transplantation group (1.5 -2.3-fold) than for the healthy adult group (8.7-1O.4-fold) for all three antigens. Similarly, there were significant differences in the geometric mean postimmunization antibody titers between the two groups for each of the three antigens. For both the B/Panama/45/90 and A/Texas/ 36/91 (HINl) antigens, the proportion of vaccinees whose titers of HI antibody reached;;::: 1:40 was significantly lower in the transplantation group than in the healthy adult group (table   2) . Overall, significant differences existed between the proportions of transplant recipients (16%-26%) and the proportions of young healthy adults (72%-86%) whose titers of HI antibody to each of the three antigens rose~4-fold (P < .0001 for each antigen).
Responses to influenza immunization in those with low preimmunization antibody titers. Because of the possible confounding effect of high preimmunization HI antibody titers in the transplant recipients, the analysis of antibody responsiveness was repeated after exclusion of patients with high ( ;;::: 1:40) baseline titers. This adjustment resulted in groups with more comparable baseline HI titers (table 3) . Although statistically significant differences still existed for two antigens, the titers averaged within one two-fold dilution for all three antigens. When the responses to the vaccine were compared by examination of the magnitude of antibody responses, the transplantation group had inferior responses to all three antigens. In addition, there was a significant difference found between the transplantation and comparison groups for all three antigens when the proportions of subjects with a~4-fold rise in antibody titer were compared. Depending on the antigen, the proportions of persons with a ;;:::4-fold rise in titer ranged from 23% to 38% in the transplantation group and 86%-100% in the healthy adult group (P < .01 for each antigen).
Factors irif/uencing response. To examine which factors within the transplant recipient group might have contributed to reduced antibody responses, those transplantation patients whose titers increased~4-fold were compared with those whose titers increased <4-fold with respect to the following factors: age; gender; race; type of transplant; history of smoking; history of diabetes; obesity; type, dosage, and duration of each immunosuppressive-drug regimen (prednisone, cyclosporine, or azathioprine); previous immunization (in 1991 and 1992); preimmunization titers of ;;::: 1:40; and history of rejection (table 4) .
For each antigen, no significant difference could be found between those patients who had a fourfold rise in HI antibody titer and those who did not for most of these variables. However, there was a significantly lower rate of fourfold rises in antibody titer to the A/Beijing/32/92 antigen among those transplant recipients who had preimmunization titers of~1:40 (3.5% vs. 41.4%; P = .001) and to the A/Texas/36/91 (HINl) antigen among such patients who had received influenza vaccines in 1992 or 1991 and among those whose preimmunization titers were~1:40 (zero vs. 34.9%; P < .0001).
Multiple linear regression was perfonned for the transplantation group in order to detennine if any of the explanatory variables had any significant association with the distribution of postimmunization titers after the other variables were con- tion antibody titers, we found that multiple logistic analysis of fourfold rises in titers with each of the explanatory variables did not result in any significant coefficients for any of the three antigens. This indicated that none of the comparative factors had an association with a fourfold response after the effects of the remaining comparative factors were controlled for.
Booster Immunization Study
Nineteen of 23 heart transplant recipients enrolled in the dual-immunization protocol completed all portions of the study; for the other four, serum samples from only two time points were available. Prior to immunization, 3 patients (14%) had HI antibody titers of~1:40 to all 3 antigens in the vaccine, 8 (38%) had such titers to 2 antigens, and I (5%) had such a titer to a single antigen. Specifically, 6 patients had preimmuni- For each of the three antigens a single dose of vaccine resulted in a statistically significant rise in titer of antibody (P < .009) (figure 1). The response was best to A/Texas/36/91 (H1N1); 53% ofpatients had a fourfold rise in titer of antibody following a single dosing of vaccine. In comparison, 28% responded to A/Shangdong/9/93 (H3N2) and 25% to B/Panama/45/90. The second dose did not enhance the response in a statistically significant fashion for any of the antigens ( figure  I ). Only one patient had a fourfold rise in titer and a protective level of antibody to both of the influenza A antigens after the second immunization. As with the prior year's study, response to vaccination was independent of the level of immunosuppression, presence or absence of obesity, and smoking history. The patients who had received a transplant most recently were less likely than the other recipients to have an antibody response to all three antigens (P == .058). This was independent of their cyclosporine doses. Immunization with the 1993 -I994 influenza vaccine did correlate with a failure to respond to A/Texas/36/91 (HlNl) (P = .030) but had no impact on response to the other two antigens.
Discussion
The current study found that solid organ transplant recipients (including recipients of heart, lung, kidney, or liver allografts) who were receiving immunosuppressive drugs had impaired antibody responses to the 1993 -1994 trivalent influenza vaccine as compared with the responses ofyoung healthy individuals. Postimmunization HI antibody titers were significantly lower for all three of the antigens, and titers of HI antibody rose~4-fold in significantly fewer solid organ transplant recipients than in healthy subjects for all three antigens.
Our analysis was confounded by the finding that, between the transplantation and comparison groups, there were significant differences in the preimmunization titers of antibody to the vaccine antigens and in the proportions of those with high baseline titers of antibody (~1:40) to the A/Beijing/32/92 (H3N2) and B/Panama/45/90 antigens. These differences may have been related in part to the high proportion of transplant recipients who had undergone immunization in the preceding year (38% of patients). The previous year's vaccine contained the same HINI and B antigens but a different H3N2 antigen (A/Beijing/353/89). In order to control for this baseline difference between the groups, the analyses were repeated after elimination of paired titers with baseline values of~I :40. Our findings indicated that significant differences in postimmunization titers and in the proportion of titers that increased fourfold for each of the three antigens persisted between the two groups, even after elimination of patients whose baseline titers were high.
Our findings and those of most previous studies (11) (12) (13) (14) of renal transplantation patients indicate that some solid organ transplant recipients have reduced antibody responsiveness to influenza vaccines. The largest subset of our transplantation population was the heart transplant cohort. To our knowledge, only one other study ( consisting of 18 patients) has been done on influenza vaccine in heart transplant recipients [8] . Only 39% of those 18 cardiac transplantation patients had a~4-fold rise in titer ofHI antibody to the influenza A antigen. Similarly, evaluation of both of our studies demonstrated that only 21 %5 3% of our cardiac transplantation patients had~4-fold rises in titer of antibody, depending on the antigen, following a single dosing of vaccine. After exclusion of those whose preimmunization titers were~I :40, 28%~47% had a~A-fold rise in titer of HI antibody in response to a single dose of vaccine.
We were unable to find previous studies ofthe immunogenicity of influenza vaccine in lung or liver transplant recipients for comparison with our experience. In our study, the HI antibody titer rose~4-fold in only zero to 13% of lung transplant recipients and 15%-31% of liver transplant recipients, depending on the antigen. Although there were limited numbers of lung and liver recipients, these findings suggest that certain solid organ transplant types may be associated with especially poor antibody responses.
In order to determine the cause of the reduced antibody response among the transplant recipients, comparisons were made regarding many potential factors and vaccine respon-siveness for each ofthe three antigens within the transplantation group. The only factors that were associated with significant differences between the proportions of those with and without a fourfold increase in antibody were preimmunization titers of 1:40 for the A/Beijing/32/92 antigen and A/Texas/36/9l (H1N 1) antigen and previous influenza vaccination (in 1991 and 1992) for the A/Texas/36/9l (HlNl) antigen. The same A/Texas antigen was contained in the 1992 vaccine. Our findings support those of a previous study that demonstrated that kidney transplant recipients who have low geometric mean preimmunization HI antibody titers are more likely to have significant antibody responses to the influenza vaccine [19] . In addition, we documented that immunity to a given antigen can be sustained over at least a I-year period.
Booster doses of influenza vaccine have been examined in limited studies of patients with malignancies who were receiving chemotherapy, of T cell-depleted bone marrow transplant recipients, and of kidney transplant recipients in the precyclosporine era [13, [20] [21] [22] . Serial immunization did boost the response in certain patients with cancer and may have also boosted responses in kidney transplant recipients who were not receiving cyclosporine [13, 20, 21] . This strategy appears to have no added efficacy in the T cell-depleted bone marrow transplant patient [22] . Similarly, our study demonstrated minimal benefit from a second dose of vaccine for heart transplant recipients. In our experience, in the majority of cases in which a protective antibody level was going to develop and/ or the titer of HI antibody was going to rise fourfold, one or both occurred following administration of a single dose of trivalent influenza vaccine.
One limitation of our cohort study was the difference in age distribution in the groups compared in the first phase of the study. The young healthy group was part of a parallel study to determine maximal responsiveness to the vaccine. We chose this group rather than an age-matched control group because we wanted to compare the transplant recipients' responses to the optimal responses to this vaccine. Although some studies have shown age-related declines in immunogenicity, others have indicated that response rates are broadly comparable among healthy young and older adults [23, 24] .
Unfortunately, our findings did not provide a clear assessment of which factors are involved in the poor antibody responses and, more importantly, what might be done to produce more consistent responses. Studies to determine reliable guidelines for predicting influenza vaccine response in the transplantation population would aid in determining who might benefit most from seasonal chemoprophylaxis with amantadine or rimantadine as a means of preventing influenza A virus infection [25] .
In conclusion, the results of this study clearly indicate that solid organ transplant patients receiving chronic immunosuppressive drug therapies have reduced responsiveness to inactivated influenza vaccines. It remains to be determined whether higher antigen doses might increase responsiveness in this population. Booster immunizations with the current formulation of the vaccine do not appear to improve vaccine response in solid organ recipients receiving cyclosporin A. It is worth noting that the majority of transplant recipients in our study had relatively high HI antibody titers (~1:40) post-immunization, particularly to the H3N2 subtype viruses, which have been associated with the highest morbidity and mortality in high-risk populations. Moreover, a protective antibody level was sustained from year to year in some patients. These findings indicate that annual immunization remains a useful intervention.
